- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06268769
Tacrolimus C:D-Verhältnis gemessen bei Empfängern von Nierentransplantaten, die mit einmal täglich verabreichten Arzneimitteln mit verzögerter Wirkstofffreisetzung behandelt wurden (TaC:Drop)
Multizentrische, offene, randomisierte, zweiarmige Parallelgruppen-Überlegenheitsstudie zur Bewertung der Bioverfügbarkeit und Praktikabilität von zwei einmal täglichen Tacrolimus-Formulierungen, Envarsus® im Vergleich zu Advagraf™, verabreicht bei Empfängern von Nierentransplantaten
The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.
The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.
Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.
Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Aachen, Deutschland, 52074
- University Hospital Aachen, Department of General, Visceral and Transplant Surgery
-
Berlin, Deutschland, 10117
- Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
-
Bochum, Deutschland, 44892
- Knappschaft Clinic, University Hospital Bochum, Department of Surgery
-
Dresden, Deutschland, 01307
- University Hospital Dresden, Division of Nephrology
-
Hamburg, Deutschland, 20251
- University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
-
Hanover, Deutschland, 30625
- Hannover Medical School, Department of General, Visceral and Transplant Surgery
-
Jena, Deutschland, 07747
- University Hospital Jena, Internal Medicine III, Nephrology
-
Mainz, Deutschland, 55131
- University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
-
Mannheim, Deutschland, 68167
- University Hospital Mannheim, Medical Clinic V
-
Munich, Deutschland, 81377
- LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
-
Münster, Deutschland, 48149
- University Hospital Münster, Medical Clinic D
-
Regensburg, Deutschland, 93053
- University Hospital Regensburg, Department of Nephrology
-
Würzburg, Deutschland, 97080
- University Hospital Würzburg, Medical Clinic I, Department of Nephrology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Signed and dated written informed consent
- Adult (≥18 years old) male or female
- Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
- ABO blood type compatible with the donor kidney
- Able to swallow an oral formulation of tacrolimus in tablet or capsule form
Exclusion Criteria:
- Multi-organ transplantation
- Any previous solid organ transplantation (other than a first kidney allograft)
- For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
- Patient and/or donor is positive for active HCV, HBV or HIV infection
- History of any malignancy that could not be curatively treated
- Ongoing abuse of drugs or alcohol
- Signs of advanced liver disease or any signs of liver decompensation
- Ongoing uncontrolled systemic infection
- Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
- Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
- Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
- Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
- Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
- Inability to freely give informed consent (e.g. individuals under legal guardianship)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Envarsus
Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Andere Namen:
|
|
Aktiver Komparator: Advagraf
Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Zeitfenster: 12 weeks after kidney transplantation
|
To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory. |
12 weeks after kidney transplantation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anteil der Patienten mit Talspiegeln, die unter, innerhalb oder über dem Zielbereich liegen
Zeitfenster: 4 Tage, 14 Tage, 28 Tage und 12 Wochen nach der Nierentransplantation
|
4 Tage, 14 Tage, 28 Tage und 12 Wochen nach der Nierentransplantation
|
|
|
Mittlerer Tacrolimus-Talspiegel und interpatiente Variabilität (Bereich) der Tacrolimus-Talspiegel
Zeitfenster: 4 Tage, 14 Tage, 28 Tage und 12 Wochen nach der Nierentransplantation
|
4 Tage, 14 Tage, 28 Tage und 12 Wochen nach der Nierentransplantation
|
|
|
Mittlere Tagesdosis von Tacrolimus und interpatiente Variabilität (Bereich) der Tacrolimus-Tagesdosis
Zeitfenster: 4 Tage, 14 Tage, 28 Tage und 12 Wochen nach der Nierentransplantation
|
4 Tage, 14 Tage, 28 Tage und 12 Wochen nach der Nierentransplantation
|
|
|
Variabilität des C/D-Verhältnisses und der Tagesdosis innerhalb des Patienten
Zeitfenster: Gemessen über die Zeitpunkte: Tag 4, Tag 14, Tag 28 und Woche 12
|
Gemessen über die Zeitpunkte: Tag 4, Tag 14, Tag 28 und Woche 12
|
|
|
Inzidenzrate begründeter Biopsien
Zeitfenster: 12 Wochen nach Nierentransplantation
|
12 Wochen nach Nierentransplantation
|
|
|
Inzidenzrate akuter Abstoßungsepisoden, die eine Behandlung erfordern
Zeitfenster: 12 Wochen nach Nierentransplantation
|
12 Wochen nach Nierentransplantation
|
|
|
Inzidenzrate steroidresistenter Episoden einer durch Biopsie nachgewiesenen akuten Abstoßung
Zeitfenster: 12 Wochen und 1 Jahr nach der Nierentransplantation
|
12 Wochen und 1 Jahr nach der Nierentransplantation
|
|
|
Inzidenz von CMV- und BKV-Infektionen (einschließlich Organmanifestation, falls relevant)
Zeitfenster: 12 Wochen und 1 Jahr nach der Nierentransplantation
|
12 Wochen und 1 Jahr nach der Nierentransplantation
|
|
|
Häufigkeit, Art, Schwere und Schwere von Nebenwirkungen (ARs)
Zeitfenster: 12 Wochen und 3 Jahre nach Nierentransplantation
|
12 Wochen und 3 Jahre nach Nierentransplantation
|
|
|
Blutdruck
Zeitfenster: 12 Wochen und 1, 2, 3 Jahre nach Nierentransplantation
|
12 Wochen und 1, 2, 3 Jahre nach Nierentransplantation
|
|
|
Auftreten von Magen-Darm-Erkrankungen, die eine diagnostische Untersuchung erfordern
Zeitfenster: 12 Wochen und 3 Jahre nach Nierentransplantation
|
12 Wochen und 3 Jahre nach Nierentransplantation
|
|
|
Wiederauftreten einer primären Nierenerkrankung
Zeitfenster: 12 Wochen und 3 Jahre nach Nierentransplantation
|
12 Wochen und 3 Jahre nach Nierentransplantation
|
|
|
Inzidenz von De-novo-DSA
Zeitfenster: Wird innerhalb des ersten Jahres nach der Nierentransplantation festgestellt
|
Wird innerhalb des ersten Jahres nach der Nierentransplantation festgestellt
|
|
|
Dosierung und Dauer der Behandlung mit Glukokortikosteroiden
Zeitfenster: 12 Wochen und 1, 2, 3 Jahre nach Nierentransplantation
|
12 Wochen und 1, 2, 3 Jahre nach Nierentransplantation
|
|
|
Inzidenz und Zeit bis zur Untersuchung des Behandlungsabbruchs
Zeitfenster: 3 Jahre nach Nierentransplantation
|
3 Jahre nach Nierentransplantation
|
|
|
Inzidenz, Zeitpunkt und Grund für den Abbruch des Patienten aus der Studie
Zeitfenster: 3 Jahre nach Nierentransplantation
|
3 Jahre nach Nierentransplantation
|
|
|
Time to reach the first trough level in target range
Zeitfenster: Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading |
Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
|
Tacrolimus concentration/dose (C/D) ratio
Zeitfenster: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site. |
4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
|
Treatment failure rate
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause) |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Time to treatment failure after transplantation
Zeitfenster: Measured until 3 years after kidney transplantation
|
Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause) |
Measured until 3 years after kidney transplantation
|
|
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition. |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of graft failure
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Mortality rate
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Mortality rate measures death from any cause |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Graft function measured by eGFR (estimated glomerular filtration rate)
Zeitfenster: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
eGFR calculated according to the CKD-EPI formula |
4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of delayed graft function
Zeitfenster: Measurable within the first 2 weeks after kidney transplantation
|
Delayed graft function is defined as the need for more than one episode of dialysis after transplantation |
Measurable within the first 2 weeks after kidney transplantation
|
|
Incidence rate of primary non-function of the renal allograft
Zeitfenster: Measurable within the first 12 weeks after kidney transplantation
|
Primary non-function is defined as the necessity for ongoing chronic dialysis |
Measurable within the first 12 weeks after kidney transplantation
|
|
Incidence of hepatotoxicity
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence of de novo tremor
Zeitfenster: 12 weeks and 3 years after kidney transplantation
|
Incidence and severity of tremor based on medical assessment by the investigator |
12 weeks and 3 years after kidney transplantation
|
|
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Zeitfenster: 12 weeks and 3 years after kidney transplantation
|
The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients. |
12 weeks and 3 years after kidney transplantation
|
|
Dose of mycophenolate
Zeitfenster: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Including both mycophenolate mofetil and mycophenolic acid |
12 weeks and 1, 2, 3 years after kidney transplantation
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Bernhard Banas, MD, University Hospital Regensburg
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TaC:Drop
- 2023-503531-18-00 (Andere Kennung: EUCT Number)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .